← FDA DRUG APPROVALS

FDA ANDA · ANDA090467

LOSARTAN POTASSIUM

Sponsor: TORRENT PHARMS

APPLICATION
ANDA090467
TYPE
ANDA
ORIGINAL APPROVAL
2010-10-06
LATEST ACTION
2020-11-03
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 50MG · TABLET · ORAL
LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUMDiscontinued
LOSARTAN POTASSIUM 25MG · TABLET · ORAL

Approval history

2020-11-03Labeling · Supplement 16 · standardAP
2020-11-03Labeling · Supplement 20 · standardAP
2015-10-23Labeling · Supplement 14 · standardAP
2015-01-12Labeling · Supplement 13 · standardAP
2015-01-12Labeling · Supplement 11 · standardAP
2013-04-02Labeling · Supplement 10 · standardAP
2012-12-20Labeling · Supplement 8AP
2012-01-09Labeling · Supplement 7AP
2012-01-09Labeling · Supplement 3AP
2011-01-30Labeling · Supplement 2AP
2010-12-28Labeling · Supplement 1AP
2010-10-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →